Abstract
Objective: To investigate the clinical effects of recombinant human interleukin-2 (rhIL-2) combined with Zhenqi Fuzheng and Baofukang on cervical intraepithelial neoplasia II (CINII) combined with human papilloma virus infection. Methods: There were 593 patients diagnosed with CINII with HPV infection, including 296 in the control group and 297 in the experimental group. The control group was given only Zhenqi Fuzheng oral and Baofukang suppository vaginal medicine. The experimental group was treated with rhIL-2 injection in addition to Zhenqi Fuzheng oral and Baofukang suppository vaginal medicine which is treated for 3 months. After 3 months, Thinprep cytologic test (TCT), human papilloma virus (HPV) quantitative examination and colposcopy biopsy were reviewed. Results: After 3 months of treatment, the negative conversion rate and total effective rate of HPV in the control group were 58.11% and 70.95% respectively, and the negative conversion rate and total effective rate of the experimental group were 79.46% and 90.57% respectively. There was significant difference between the two groups (p = 0.000). The curative rate of cervical lesions was significantly higher in the test group than in the control group, 89.56%, 68.91%, respectively. The statistical difference between the two groups is significant (p = 0.000). Conclusion: It has an essential clinical value that HPV infection patients and cervical intraepithelial neoplasia II associated with HPV infection patients are treated by rhIL-2 combined with Zhenqifuzheng and Baofukang, which is safe, effective, non-invasive, reusable advantages. However, the long-term efficacy and side effects need to be further studied.
Highlights
Cervical cancer is a serious disease threatening to human health, and many studies have demonstrated that cervical cancer and cervical intraepithelial neoplasia (CIN) are infected by human papilloma virus (HPV)
It has an essential clinical value that HPV infection patients and cervical intraepithelial neoplasia II associated with HPV infection patients are treated by recombinant human interleukin-2 (rhIL-2) combined with Zhenqifuzheng and Baofukang, which is safe, effective, non-invasive, reusable advantages
This study reviewed the use of recombinant Human Interleukin 2 combined with Zhenqi Fuzheng capsule and Baofukang suppository in patients with cervical intraepithelial neoplasia II (CINII) and HPV infection diagnosed by colposcopy biopsy from January 2015 to December 2018 in the Beijing Tongren Hospital, we study the value of them in the treatment of cervical CINII and HPV infecttion, and make effective and convenient treatment plan for cervical CINII patients with HPV infection
Summary
Cervical cancer is a serious disease threatening to human health, and many studies have demonstrated that cervical cancer and cervical intraepithelial neoplasia (CIN) (including CINI, CINII, CINIII) are infected by HPV. Even when low-grade cervical intraepithelial neoplasia (CIN1) develops, the majority of these lesions regress spontaneously back to normal, in young women [4] While they have cervical CIN, in terms of CINII, CINIII, most of them will be treated with cervical conization and physical lesion, such as cold knife conization (CKC), large loop excision of the transformation zone (LLETZ), hysteroscopic conization of cervix and laser conization and so on [5]. Postoperative complications, such as wound bleeding, infection, cervical incompetence and cervical adhesions, will affect future fertility, and the cost is high. It is very crucial how to treat the HPV positive patients with CIN safely and effectively, and, how to treat relapses with low cost and easy acceptance
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
